Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 4/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.49 |
| ▸ | ITGAL | P20701 | 4/20 | 0.49 |
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935436 | 0.90 | ITGB2 (0.51) | ITGB2ICAM1ITGALTACR1ECE1 | |
| SCHEMBL3942506 | 0.89 | ACHE (0.44) | ACHETACR1LMNAGAAECE1 | |
| SCHEMBL13913164 | 0.87 | ITGB2 (0.55) | ITGB2ICAM1ITGALACHETACR1 | |
| SCHEMBL3935415 | 0.87 | ITGB2 (0.48) | ITGB2ICAM1ITGALTACR1ECE1 | |
| SCHEMBL3937190 | 0.87 | ACHE (0.50) | ACHETACR1LMNAGAACCKBR | |
| SCHEMBL4739283 | 0.85 | ITGB2 (0.59) | ITGB2ICAM1ITGALECE1ALDH1A1 | |
| SCHEMBL4738079 | 0.82 | ITGB2 (0.51) | ITGB2ICAM1ITGALECE1 | |
| SCHEMBL13902867 | 0.82 | ACHE (0.43) | ACHETACR1ECE1CCKBRALDH1A1 | |
| SCHEMBL3944062 | 0.82 | ITGB2 (0.51) | ITGB2ICAM1ITGALECE1 | |
| SCHEMBL13960308 | 0.82 | ITGB2 (0.51) | ITGB2ICAM1ITGALECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | claimed |
| WO-2009013333-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | claimed |
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | claimed |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2009013333-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009013333-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | disclosed |
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | FSHR, GNRHR, CYP19A1 | ITGB2 2779/4885ICAM1 3647/4885ITGAL 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.